{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:38:17Z","timestamp":1789609097389,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.vaccine.2023.03.071","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T08:16:55Z","timestamp":1681892215000},"page":"3285-3291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Vaccine-induced immune thrombotic thrombocytopenia post dose 2 ChAdOx1 nCoV19 vaccination: Less severe but remains a problem"],"prefix":"10.1016","volume":"41","author":[{"given":"Lisa","family":"Clarke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Brighton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev D.","family":"Chunilal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine S.M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freda","family":"Passam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Curnow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien M.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huyen A.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.vaccine.2023.03.071_b0005","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.vaccine.2023.03.071_b0010","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.vaccine.2023.03.071_b0015","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N Engl J Med"},{"issue":"10313","key":"10.1016\/j.vaccine.2023.03.071_b0020","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(21)02285-6","article-title":"Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine?","volume":"398","author":"Pavord","year":"2021","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.vaccine.2023.03.071_b0025","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood.2021015329","article-title":"Cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia after a second ChAdOx1 nCoV-19 dose","volume":"139","author":"Krzywicka","year":"2022","journal-title":"Blood"},{"issue":"10300","key":"10.1016\/j.vaccine.2023.03.071_b0030","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(21)01693-7","article-title":"Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis","volume":"398","author":"Bhuyan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.03.071_b0035","unstructured":"THANZ. Suspected Vaccine Induced Prothrombotic Immune Thrombocytopenia (VIPIT)\/Vaccine induced immune thrombotic thrombocytopenia VITT): THANZ Advisory Statement for Haematologists. 2021."},{"issue":"18","key":"10.1016\/j.vaccine.2023.03.071_b0040","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.vaccine.2023.03.071_b0045","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood.2021012938","article-title":"Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein","volume":"138","author":"Greinacher","year":"2021","journal-title":"Blood"},{"issue":"7873","key":"10.1016\/j.vaccine.2023.03.071_b0050","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-021-03744-4","article-title":"Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia","volume":"596","author":"Huynh","year":"2021","journal-title":"Nature"},{"issue":"292","key":"10.1016\/j.vaccine.2023.03.071_b0055","article-title":"Vaccine-Induced Thrombocytopenia and Thrombosis (VITT) Antibodies Recognize Neutrophil-Activating Peptide 2 (NAP2) As Well As Platelet Factor 4 (PF4): Mechanistic and Clinical Implications","volume":"138","author":"Rauova","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.vaccine.2023.03.071_b0060","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/jth.15341","article-title":"Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology","volume":"19","author":"Nazy","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.vaccine.2023.03.071_b0065","doi-asserted-by":"crossref","first-page":"245","DOI":"10.5694\/mja2.51229","article-title":"Australian and New Zealand approach to diagnosis and management of vaccine-induced immune thrombosis and thrombocytopenia","volume":"215","author":"Chen","year":"2021","journal-title":"Med J Aust"},{"key":"10.1016\/j.vaccine.2023.03.071_b0070","unstructured":"Brighton Collaboration. Updated proposed Brighton Collaboration process for developing a standard case definition for study of new clinical syndrome X, as applied to thrombosis with thrombocytopenia syndrome (TTS). v 10.16.3. May 18, 2021 2021 [Available from: https:\/\/ brightoncollaboration. us\/wp-content\/ uploads\/2021\/05\/TTSInterim-Case-Definition-v10.16.3-May-23-2021.pdf."},{"key":"10.1016\/j.vaccine.2023.03.071_b0075","unstructured":"Therapeutic Goods Association. COVID-19 vaccination \u2013Primary care approach to thrombosis with thrombocytopenia syndrome after COVID-19 AstraZeneca vaccine | Australian Government Department of Health and Aged Care 2021 [Available from: https:\/\/www.health.gov.au\/resources\/publications\/covid-19-vaccination-primary-care-approach-to-thrombosis-with-thrombocytopenia-syndrome-after-covid-19-astrazeneca-vaccine."},{"issue":"11","key":"10.1016\/j.vaccine.2023.03.071_b0080","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/bloodadvances.2021006698","article-title":"A novel flow cytometry procoagulant assay for diagnosis of vaccine-induced immune thrombotic thrombocytopenia","volume":"6","author":"Lee","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.vaccine.2023.03.071_b0085","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1056\/NEJMc2106383","article-title":"PF4 Immunoassays in Vaccine-Induced Thrombotic Thrombocytopenia","volume":"385","author":"Vayne","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.03.071_b0090","unstructured":"ATAGI. ATAGI statement on use of COVID-19 vaccines in an outbreak setting July 13th 2021. 2021 [."},{"key":"10.1016\/j.vaccine.2023.03.071_b0095","doi-asserted-by":"crossref","DOI":"10.1111\/jth.15881","article-title":"Assessment of immunological anti-platelet factor 4 antibodies for vaccine-induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: A multicenter study comprising 1284 patients","author":"Favaloro","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vaccine.2023.03.071_b0100","unstructured":"Australian Immunisation Register. https:\/\/www.health.gov.au\/topics\/immunisation\/immunisation-data\/childhood-immunisation-coverage\/immunisation-coverage-data-surveys-and-reports."},{"issue":"19","key":"10.1016\/j.vaccine.2023.03.071_b0105","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1056\/NEJMc2112760","article-title":"Decline in Pathogenic Antibodies over Time in VITT","volume":"385","author":"Schonborn","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2023.03.071_b0110","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1111\/jth.13813","article-title":"Autoimmune heparin-induced thrombocytopenia","volume":"15","author":"Greinacher","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vaccine.2023.03.071_b0115","doi-asserted-by":"crossref","DOI":"10.1111\/jth.15862","article-title":"Quantitative interpretation of PF4\/heparin-EIA optical densities in predicting platelet-activating VITT antibodies","author":"Schonborn","year":"2022","journal-title":"J Thromb Haemost"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23003791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23003791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:26:50Z","timestamp":1759404410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23003791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":23,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0264410X23003791"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.071","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine-induced immune thrombotic thrombocytopenia post dose 2 ChAdOx1 nCoV19 vaccination: Less severe but remains a problem","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2023 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}